Management of Urosepsis with C. difficile Enteritis
Treatment Considerations
- The American College of Physicians recommends ceftazidime/avibactam 2.5g IV q8h for complicated urinary tract infections caused by resistant organisms, with a strength of evidence rated as high 1
- The Infectious Diseases Society of America suggests imipenem/cilastatin/relebactam 1.25g IV q6h as an alternative option for urosepsis treatment, with a moderate strength of evidence 1
- Aminoglycosides, such as gentamicin or amikacin, can be considered for susceptible organisms, with a low strength of evidence 1
C. difficile Considerations
- Broad-spectrum antibiotics can worsen C. difficile infection by disrupting gut flora, with a high strength of evidence 2, 3
- Oral vancomycin is the preferred treatment for C. difficile enteritis, with a high strength of evidence 2
Antibiotic Selection Algorithm
- Ceftazidime/avibactam 2.5g IV q8h is the first-line therapy for urosepsis, providing excellent coverage for resistant gram-negative organisms, with a high strength of evidence 1
- Imipenem/cilastatin/relebactam 1.25g IV q6h is an alternative option, with a moderate strength of evidence 1
Concurrent C. difficile Management
- Oral vancomycin 125mg four times daily for 10 days is recommended for C. difficile enteritis treatment, with a high strength of evidence 2
- Fidaxomicin 200mg twice daily can be considered for severe C. difficile, with a moderate strength of evidence 2
Monitoring and Adjustments
- Clinical response should be assessed within 72 hours, with a moderate strength of evidence 3
- Antibiotic spectrum should be narrowed once culture results are available, with a low strength of evidence 3